Stock FUSN FUSN PHAR
Add to a list
To use this feature you must be a member
Log inSign up

Consensus FUSN PHAR

Equities

FUSN

CA36118A1003

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
21.25 USD +0.05% Intraday chart for FUSN PHAR -0.51% +121.12%
Apr. 16 TD Cowen Downgrades Fusion Pharmaceuticals to Hold MT
Apr. 09 Fusion Pharmaceuticals Inc. Presents Interim Efficacy and Safety Data from the Phase 2 TATCIST Open-Label Clinical Trial Evaluating FPI-2265 CI

Evolution of the average Target Price on FUSN PHAR

Price target over the last 5 years

History of analyst recommendation changes

1d5367060cff306.boRrefs8ftJvoqsIuzZy3JxUULnzma7DBssQ7bfDDDU.JbIsLZpWT6oLxNxxlnE9lvEjAYG-_peISoopt9-yfAEL5yMbunkGqjXt_g~333eedbe0ddc6d835baa7b3f34699e46

Analyst Recommendations on FUSN PHAR

TD Cowen Downgrades Fusion Pharmaceuticals to Hold MT
B. Riley Downgrades Fusion Pharmaceuticals to Neutral From Buy on Heels of Announced Sale to AstraZeneca, Adjusts PT to $23 From $13 MT
Bloom Burton Downgrades Fusion Pharmaceuticals to Hold From Buy, Raises Price Target to $21.50 From $20 MT
Fusion Pharmaceuticals Downgraded by RBC to Sector Perform From Outperform, Speculative Risk Removed, Price Target Raised to $21 From $16 MT
JonesTrading Downgrades Fusion Pharmaceuticals to Hold From Buy MT
Jefferies Downgrades Fusion Pharmaceuticals to Hold From Buy, Raises Price Target to $21 From $10 MT
Morgan Stanley Downgrades Fusion Pharmaceuticals to Equalweight From Overweight, Raises Price Target to $21 From $10 MT
Truist Securities Downgrades Fusion Pharmaceuticals to Hold From Buy, Adjusts Price Target to $21 From $11 MT
William Blair Downgrades Fusion Pharmaceuticals to Market Perform From Outperform MT
Raymond James Downgrades Fusion Pharmaceuticals to Market Perform From Strong Buy, Raises Price Target to $21 From $16 MT
Brookline Capital Downgrades Fusion Pharmaceuticals to Hold From Buy, Raises Price Target to $21 From $20 MT
Wedbush Downgrades Fusion Pharmaceuticals to Neutral From Outperform on Heels of Announced Sale to AstraZeneca, Adjusts PT to $24 From $13 MT
Leerink Downgrades Fusion Pharmaceuticals to Market Perform From Outperform, Lifts Price Target to $21 From $17 MT
RBC Lifts Price Target on Fusion Pharmaceuticals to $16 From $12, Sees 80% Probability of Upside, Protected Downside; Outperform, Speculative Risk Kept MT
Oppenheimer Ups Price Target on Fusion Pharmaceuticals to $15 From $13, Maintains Outperform Rating MT
Raymond James Upgrades Fusion Pharmaceuticals to Strong Buy From Outperform, Boosts Price Target to $15 From $12 MT
Fusion Pharmaceuticals Initiated at Outperform, Speculative Risk by RBC; Price Target Set at $12 Amid Bullish View on Radiopharmaceuticals MT
Oppenheimer Starts Fusion Pharmaceuticals at Outperform With $13 PT, Sees as Leading Player in Targeted Radiopharmaceutical Therapy Space MT
Raymond James Adjusts Fusion Pharmaceuticals' Price Target to $12 From $13, Keeps Outperform Rating MT
Raymond James Initiates Fusion Pharmaceuticals at Outperform Rating With $13 Price Target MT
B. Riley Adjusts Price Target on Fusion Pharmaceuticals to $13 From $10, Maintains Buy Rating MT
Wedbush Lifts Fusion Pharmaceuticals' Price Target to $13 From $12 After Acquisition News, Keeps Outperform Rating MT
B. Riley Resumes Fusion Pharmaceuticals With Buy Rating, $10 Price Target MT
SVB Securities Initiates Fusion Pharmaceuticals With Outperform Rating, Sets Price Target at $6 MT
Truist Securities Starts Fusion Pharmaceuticals at Buy With $10 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
21.25 USD
Average target price
21.55 USD
Spread / Average Target
+1.41%
High Price Target
24 USD
Spread / Highest target
+12.94%
Low Price Target
21 USD
Spread / Lowest Target
-1.18%

Consensus detail

Consensus revision (last 18 months)

Analysts covering FUSN PHAR

TD Cowen
JonesTrading Institutional Services
Bloom Burton
Morgan Stanley
Jefferies & Co.
Wedbush
Brookline Capital Markets
Raymond James
William Blair & Co.
Truist Securities
Leerink Partners
RBC Capital Markets
Oppenheimer
B. Riley
SVB Securities LLC

Ratings for FUSN PHAR

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. FUSN Stock
  4. Consensus FUSN PHAR